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Background: Tacrolimus is an immunosuppressive drug that is used to lower the activity of the patient’s immune
system to prevent organ rejection. Unfortunately, there is limited data regarding the therapeutic equivalency of
generic tacrolimus formulations especially in children. We report the case of a pediatric patient having an inability
to achieve a therapeutic trough level for tacrolimus after conversion from brand name to the generic formulation.
Case presentation: A 17-month-old male patient diagnosed with T-cell acute lymphoblastic leukemia underwent
allogeneic stem cell transplantation. The patient initially received intravenous (IV) tacrolimus for graft-versus-host
disease (GVHD) prophylaxis and achieved therapeutic levels. The patient was then switched to an oral brand
formulation of tacrolimus, and was able to maintain trough levels within the therapeutic range. After being discharged,
the patient received the generic formulation of tacrolimus from an outside pharmacy and the care team was unable to
reach therapeutic levels despite multiple dose escalations. Returning to brand name tacrolimus resulted in prompt
achievement of therapeutic levels.
Conclusions: A likely etiology for the inability to achieve therapeutic trough levels in this patient is the change in
formulation from brand formulation to generic version. Other factors including drug-drug interaction, preparation of
the medication by a different pharmacy, drug-food interaction and genetic factors were also considered. Physicians
and pharmacists must be aware of the inability to achieve targeted therapeutic concentrations of tacrolimus resulting
from the conversion of brand name to the generic formulation until these generic formulations are tested in clinical
trials in a pediatric population.
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Tacrolimus is a commonly used calcineurin inhibitor used
to induce immunosuppression and prevent graft-versus-
host disease as well as rejection in patients receiving both
hematopoietic and solid organ transplantation [1-3].
When approved in 1994, it was marketed under the brand
name Prograf®. The first generic version was approved by
the FDA in 2009 [4]. In practice there is a sentiment
among physicians and patients that generic immunosup-
pressants differ in efficacy from their brand versions [5].
The FDA uses a simplified process for the approval of
generic drugs called an abbreviated new drug application* Correspondence: npinto1@peds.bsd.uchicago.edu
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unless otherwise stated.(ANDA) [1]. In that process the generic drug is tested only
in healthy volunteers with ages between 24–36 years old.
The FDA defines bioequivalence as “the absence of a
significant difference in the rate and extent to which the
active ingredient or active moiety in pharmaceutical
equivalents or pharmaceutical alternatives becomes avail-
able at the site of drug action when administered at the
same molar dose under similar conditions in an appropri-
ately designed study.” Currently, the FDA does not place
immunosuppressants within a special category when
evaluating the bioequivalency between generic and brand
name drugs [5].
Although there are 5 generic formulations of tacroli-
mus currently available in the U.S. [6], there is limited
data to confirm their therapeutic equivalency. In this case
report we describe a 17-month-old boy with T-cell acute. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lated allogeneic stem cell transplant approximately two
months prior. He was initially started on tacrolimus (i.v.)
at the time of transplant for GVHD prophylaxis, and after
changing to oral brand formulation in the hospital he was
still in the therapeutic range. Once he was discharged, he
received generic tacrolimus from an outside pharmacy,
and was found to be sub-therapeutic despite escalating
doses of medication.
Case presentation
A 17-month-old male patient was diagnosed with T-cell
acute lymphoblastic leukemia at 10 months of life, when
he was noted to have a white blood cell count of 950,000
with peripheral leukemic blasts as well as systemicFigure 1 Tacrolimus blood levels compared to its daily dose. (A) Bloo
version. Day 0 was when patient received matched unrelated allogeneic st
(ng/ml). Red lines represent the upper and lower limits of tacrolimus thera
dose per day (mg/kg) and voriconazole dose per day (mg/kg) for the samesymptoms. Subsequently he received multiple courses
of chemotherapy, and then underwent a matched unre-
lated allogeneic stem cell transplant at the age of
15 months. A combination of Busulfan, Fludarabine and
Alemtuzumab were utilized for myeloablation prior to allo-
geneic stem cell transplantation from a matched unrelated
donor. Subsequently he was initially started on IV tacroli-
mus (0.033 mg/kg) for GVHD prophylaxis, and achieved
therapeutic levels (Figure 1). Approximately one month
after transplant in anticipation of being discharged, the pa-
tient was switched to an oral brand name formulation of
tacrolimus (Prograf®), and was able to maintain trough
levels in the prescribed therapeutic window (Figure 1). The
patient was discharged approximately one week later with
generic tacrolimus suspension dosed at 0.15 mg/kg POd levels of tacrolimus when patient administered brand or generic
em cell transplant. X represents the patient’s blood tacrolimus levels
peutic trough level. (GVHD): graft-versus-host disease. (B) Tacrolimus
time interval.
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macy. Subsequently, he was unable to reach therapeutic
levels despite multiple escalations in dosage to a maximum
dosage of 0.31 mg/kg PO twice daily (Figure 1). Also
during this time the patient’s dose of Voriconazole was re-
duced from 16.26 mg/kg (therapeutic dosage) to 8.46 mg/
kg PO daily (expected prophylactic dosage). During this
period when his doses were escalated due to inadequate
trough levels, multiple investigations were made, and the
pharmacist compounding the medication was contacted.
According to the outside pharmacy, the pharmacist com-
pounded the medication in a similar fashion to the in-
patient pharmacy and the solvents used were the same.
The compounding in the inpatient and outside pharmacy
followed a straightforward procedure involving mixing the
contents of 6 tacrolimus capsules (5 mg each) with 30 mls
of Syrup and 30 mls of oral suspending vehicle. Trough
levels were drawn at appropriate times, and the family was
compliant with the medication.
Initially after transplant the patient manifested evidence
of skin GVHD with mild skin erythema; topical steroids
were initiated two weeks prior to discharge and were con-
tinued as an outpatient. The child’s skin GVHD showed
marked improvement with topical steroids yet began to
flare a few weeks later when he presented to the clinical
pharmacology service for inability to reach a therapeutic
level for tacrolimus. Tacrolimus is one of the primary
agents used to induce immunosuppression and combat
GVHD in bone marrow transplant patients; hence the pa-
tient’s resurgence of skin GVHD is likely further manifest-
ation of sub-therapeutic tacrolimus levels.
At the time of the initial encounter for skin GVHD and
subtherapeutic tacrolimus levels the patient was taking
the following medications: acetaminophen (15 mg/kg by
oral route every 6 hours as needed for pain for 30 doses),
diphenhydramine (1 mg/kg by oral route every 6 hours as
needed), famotidine (0.53 mg/kg by oral route twice daily),
hydrocortisone 0.5% topical ointment (1 application by
topical route twice daily), ondansetron (0.15 mg/kg by oral
route every 8 hours as needed for nausea/vomiting),
sulfamethoxazole-trimethoprim (13.3 mg/kg/2.6 mg/kg)
by oral route twice daily on Monday, Tuesday, Wednesday),
valacyclovir (29 mg/kg by oral route every 8 hours), vorico-
nazole (oral suspension 10 mg/kg by oral route twice daily),
and multivitamins. Patient had an appropriate response to
opiates (including codeine) and other medications per the
caregivers. Patient did not have any adverse outcomes with
surgery and anesthesia.
Review of systems at the initial encounter indicated the
patient was irritable due to pruritus. The patient had a gen-
eralized rash that caused him to wake at night and necessi-
tated the use of diphenhydramine for symptomatic relief.
He also had loose stools yet normal number of bowel
movements daily, and was tolerating his diet appropriately.He did not have fever, or a change in appetite or activity.
Physical exam showed a fine erythematous rash scattered
on face and extremities. Excoriations were present on the
lower back and extremities as well. The clinical pharmacol-
ogy service was consulted at this time to evaluate the eti-
ology of the patient’s inability to reach therapeutic trough
levels of tacrolimus.
Discussion
In clinical practice we utilize trough level concentration
as a measure of the exposure to tacrolimus. A recent study
showed that trough level concentrations can be used as a
reliable surrogate measure for area under the curve (AUC)
for patients in normal clinical practice receiving generic
tacrolimus [7].
Several factors, which may have contributed to the
subtherapeutic trough levels upon conversion to generic
formulation, were considered. For example, although the
outside pharmacy claimed that it prepared the medication
in a similar way as the hospital pharmacy, it still remains a
possibility that this pharmacy had less experience in com-
pounding narrow therapeutic index drugs (NTI) which
may have contributed to the difference in drug levels. Add-
itionally, it’s known that voriconazole can inhibit CYP3A4,
decreasing the metabolism of tacrolimus and increasing its
blood concentration [8]. As shown in Figure 1, the patient’s
dose was reduced from 16.26 mg/kg (therapeutic dosage)
to 8.46 mg/kg PO daily (expected prophylactic dosage) that
may have resulted in increasing the metabolism of tacroli-
mus and decreasing its concentration in the plasma. The
dose of voriconazole was increased back to 19.5 mg/kg/day
at the same time of switching back to the brand name
tacrolimus and the rise of blood tacrolimus levels.
Therefore the change in voriconazole dose could have
contributed to the change in blood tacrolimus levels but
because the patient maintained therapeutic drug concen-
trations after discontinuing voriconazole on day +106, the
clinical pharmacology consultation team hypothesized that
drug-drug interactions did not fully contribute to the ob-
served drop in tacrolimus levels.
Additionally, it’s unlikely that famotidine administra-
tion caused the environment in the stomach to be alka-
line and the patient was given it both while in the
hospital and after being discharged. Moreover, clinical
literature has been inconclusive regarding the impact of
antacids on immunosuppresants such as tacrolimus [9].
Moreover, the prevention of tacrolimus absorption due
to the concomitant administration of iron or other vitamins
is not supported by any clinical literature. In addition to
that, the patient received the same iron and vitamins while
he was in the hospital. Finally, the other drugs he adminis-
tered (Acetoaminophen, diphenhydramine, ondansetron,
sulfamethoxazole-trimethoprim and valacyclovir) were not
reported to interact with tacrolimus. Furthermore, the
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hospital and after being discharged. Finally, he didn’t have
any food changes that may have contributed to the
changes in bioavailability between the two products when
they were given orally.
Pharmacogenetic factors were unlikely to have contrib-
uted. The CYP 3A5*1 allele has been implicated in lower
tacrolimus trough levels than patients with CYP3A5*3
[10]. This allelic variant, though important, is unlikely to
play a critical role for our patient, as he was able to main-
tain therapeutic trough levels with appropriate dosage of
tacrolimus.
The conversion from brand to generic formulation
could have contributed to the inability to achieve thera-
peutic levels of tacrolimus. In general, studying the effect
of switching to generic tacrolimus in pediatric patients is
not well explored. The only available study that evaluated
switching to generic tacrolimus in children was done in
renal transplant patients [4]. In that study, both trough
and serum creatinine levels were retrospectively analyzed
for four patients (with ages range between 8–22 years
old). Although trough levels were generally comparable
before and after switching from brand name to generic ta-
crolimus, interindividual differences existed. Serum cre-
atinine levels were identical pre- and post- switch in three
of the four patients. The fourth patients suffered from
acute rejection immediately after switching to the generic
formulation. This was accompanied by a dramatic increase
in the patient’s serum creatinine level.
Contradictory results exist regarding the clinical equiva-
lency of brand name tacrolimus formulations to their
generic versions in the adult population. Despite the
aforementioned study that showed that brand name tacro-
limus and generic formulations may not be bioequivalent,
other studies have showed that they are bioequivalent. For
example, one study examined the efficacy and safety of the
generic oral capsules of tacrolimus (TacroBell®) in de novo
renal transplantation [11]. The study recruited ninety-six
renal transplant recipients from 9 transplantation centers
in South Korea. In general, the acute rejection and graft
survival rates were comparable to brand name treatment.
One unresolved issue with this study is that it was carried
out in low risk populations with only short term follow
up. Another recent study evaluated seventy conversions,
of brand name tacrolimus to the generic tacrolimus
(Sandoz), from four centers from patients after kidney,
liver or multiorgan transplant [12]. This study showed
that trough levels and dosage needed are similar be-
tween brand name tacrolimus and its generic formu-
lation. Furthermore, a retrospective analysis of the
electronic records and clinical databases for 234 clinic-
ally stable adult transplant recipients (renal, liver, and
heart) whose tacrolimus was converted from brand
name to a generic formulation recently occurred [13].Trough levels were generally comparable between the
two formulations. No deaths or acute rejections were
reported but thirty-six patients required dose titration.
Another open-label, multicenter pilot study in South
Korea evaluated 57 patients receiving generic tacrolimus
and corticosteroids after liver transplantation [14]. This
group of patients was then compared to another retro-
spectively matched control group consisting of living
donor liver transplant recipients at another center who
received brand name tacrolimus. Adverse events were
generally comparable between the two patient popula-
tions and no patients died during this study. In addition
to that, a multicenter crossover pharmacokinetic study
in which patients would receive both the generic and
brand name formulation for 14 days and then crossover
revealed that Sandoz generic tacrolimus has a similar
pharmacokinetic profile to Prograf® in kidney transplant
patients [15]. Finally, a recent prospective study showed
that stable kidney transplant recipients can be converted
to Sandoz generic tacrolimus by closely monitoring both
plasma creatinine levels and trough concentration of
tacrolimus [16].
For our patient, we recommended that the patient re-
turn to brand name formulation, after which the patient
had therapeutic tacrolimus levels as well as resolution of
his GVHD flare.
There are a number of reasons why the current bio-
equivalence studies may be inadequate for the approval of
generic immunosuppressants [17]. First, studies in healthy
subjects may not be extrapolated to transplant recipients.
Second, steady state conditions may not be represented by
single dose studies. Third, the allowance of the confidence
interval to be (80%–125%) may be too variable for drugs
with a narrow therapeutic index such as immunosup-
pressants. Finally, children are excluded from these
bioequivalence studies. For this reason the American
Society of Transplantation strongly supported studies to
demonstrate bioequivalence in potentially at risk pa-
tients, especially children [18].Conclusions
The fact that previous studies regarding the bioequiva-
lency of generic and brand name tacrolimus were al-
most exclusively done in adult human highlights the
importance of testing them in pediatric patients as well
as those who have undergone allogeneic stem cell trans-
plantation. Results from adult case studies cannot be ex-
trapolated for children. Until the use of various generic
formulations of tacrolimus can be evaluated in a large
randomized clinical trial in children, physician and
pharmacists must be aware of possible adverse events
following a conversion from brand name to the generic
form of tacolimus.
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